article thumbnail

STAT+: Pharmalittle: Eisai exec who helped lead Alzheimer’s drug development to retire; Express Scripts adds three Humira biosimilars to preferred formulary

STAT

The drug is the first medicine shown to slow progression of the disease, which afflicts some 6 million Americans. Express Scripts will add three biosimilar versions of AbbVie’s blockbuster arthritis treatment Humira to its list of preferred drugs , Reuters notes. The

article thumbnail

Analyzing the impact of biosimilars on biologic drug development pipelines

Drug Patent Watch

Biosimilars, which are biologic drugs that are highly similar to an already approved biologic drug, are transforming the pharmaceutical industry. As patents for original biologic drugs expire, biosimilars are becoming increasingly important, offering more affordable treatment options for patients and healthcare systems.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Just how much money do drugmakers gain from patent extensions?

STAT

Extending patent protection doesn’t just stretch a drug’s profits — in some cases, doing so can lead to its most significant revenue period, according to a recent analysis published by the Initiative for Medicines, Access & Knowledge, or I-MAK, a nonprofit advocating for drug pricing reforms.

article thumbnail

AI-driven biosimilar manufacturing partnership announced

European Pharmaceutical Review

Sandoz and Just – Evotec Biologics have announced a partnership to develop and manufacture multiple biosimilars. Within the agreement, Sandoz will gain access to an artificial intelligence (AI) -driven technology platform that delivers fully integrated drug substance development and continuous manufacturing.

article thumbnail

Sandoz to build Slovenian biosimilar development facility

European Pharmaceutical Review

To support future growth of its biosimilar pipeline, Sandoz is planning to build a Biosimilar Technical Development Center in Slovenia. The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026.

article thumbnail

Is CAR-T safe for early-stage patients?

STAT

Damian here with a reminder that my colleague Ed Silverman is hosting a discussion today about the long-awaited arrival of Humira biosimilars and all they portend for drug costs, insurance coverage, and pharma revenues.    Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Read the rest…

article thumbnail

STAT+: A Q&A with the global head of Boehringer Ingelheim’s innovation unit

STAT

Oh, it was also the day the company launched another Humira biosimilar.     There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health.